Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.55 |
| ▸ | MAOB | P27338 | 11/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148164 | 0.81 | KMO (0.67) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL17149219 | 0.74 | CSNK2A1 (0.71) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL30294205 | 0.71 | CSNK2A1 (0.71) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL5585452 | 0.71 | MAPT (0.62) | MAOAMAOBMEN1KMT2AMAPT | |
| SCHEMBL10962764 | 0.71 | KMT2A (0.74) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL5118824 | 0.70 | ESR1 (0.59) | MEN1KMT2AMAPTALDH1A1POLB | |
| SCHEMBL15689083 | 0.70 | RAB9A (0.73) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL31247865 | 0.69 | MAPT (0.67) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL8355111 | 0.69 | MEN1 (0.65) | MAOAMAOBMEN1KMT2ACSNK2A1 | |
| SCHEMBL6959871 | 0.69 | KMT2A (0.61) | MAOAMAOBMEN1KMT2ACSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710237-B2 | Small molecule inhibitors of kynurenine-3-monooxygenase | THE J. DAVID GLADSTONE INSTITUTE (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022052-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022052-A1 | SMALL MOLECULE INHIBITORS OF KYNURENINE-3-MONOOXYGENASE | KMO, KYNU, TDO2 | MAOA 8/4885MAOB 7/4885MEN1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.